Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a German company located in Munich. The firm produces copper and metal powders. Robert Saller and Peter Kufer are the current co-CEOs of the firm. On June 13, 2002 ECKA Granulate GmbH & Co. KG acquired Amgen Research (Munich) GmbH from Aurubis AG.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Shanghai Keqi Pharmaceutical Technology Co., Ltd., established on 2018-11-11, The scope of business includes engaging in biological,Technology development in the field of medical science and technology,technical consulting,technology transfer,Technical Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Xi'an Yufan Biotechnology Co., Ltd., established on 2016-07-26, Business scope includes biological,pharmaceutical products,Medical Device Technology Development,technology transfer,Technical Consulting and Technical Services;Business Management Consulting;Experimental equipment and consumables,biological reagent(non-hazardous,monitor,precursor chemicals)R & D and sales;Import and export of goods and technology(country restrictions,Excluding goods and technologies that are prohibited and subject to approval for import and export);First,two,Research and development of three types of medical devices,production and sales;Basic software service;Application software service;data processing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China.

Wuhan Sian Medical Technology Co., Ltd., established on 2015-07-14, Business scope includes technology development of biological and medical technology,technology transfer;Research and development of pharmaceuticals and their raw materials,production and sales;Research and development of diagnostic and testing technology for biomedical therapeutic products,technology transfer;Development of new clinical diagnostic kits;Gene molecular detection technology research,technology transfer,technical consulting;biological laboratory equipment,Reagent(Does not contain dangerous goods)and consumables research and development,production and sales;Import and export,Technology Import and Export,Agent import and export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state);(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

Part of Cellular Biomedicine Group, Inc., Shanghai Cellular Biopharmaceutical Group Ltd. is a company headquartered in China. The firm develops therapies for cancer and degenerative diseases.

CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.

MingMed is a Chinese company with global competitiveness in independent drug research and development. The company's main product pipeline includes, among other things, ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs, and pet immune drugs, as well as a number of potential First-in-Class innovative drugs that have reached the clinical stage.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Shenzhen Feipeng Biotherapy Co., Ltd., established on 2015-12-31, Business scope includes general business items:R&D of biopharmaceuticals;Biomedical technology transfer;Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:

ounded in 2014, Wuhan Bio-Raid Biotechnology Co., Ltd. is a high-tech enterprise focusing on CAR-T cell immunotherapy. Bio-Raid has developed a number of patented technologies, and established a broad pipeline of CAR-T product candidates covering blood and solid tumors and HIV areas of significant unmet medical need.

Huadao (Shanghai) Biomedical Co., Ltd. engages in the development of biomedical technology. It also engages in the research and development of pharmaceutical products and provides technology consulting and transfer services. The company was founded by Xue Jun Yu on September 30, 2017 and is headquartered in Shanghai, China.